Slide 1: Rapid Progress on the data-driven Autobahn to Cures
Rapid Progress on the data-driven Autobahn to Cures Evotec SE, 9M 2021 Interim Statement, 11 November 2021
Slide 2: Cautionary statement regarding forward-looking statements
Cautionary statement regarding forward-looking statements This presentation (including any information which has been or may be supplied in writing or orally in connection herewith or in connection with any further inquiries) is being delivered on behalf of Evotec SE (the “Company”, “we,” “our” or “
Slide 3: Welcome to 9M 2021: The Management Team
Welcome to 9M 2021 The Management Team Werner Lanthaler1) Enno Spillner1) Craig Johnstone Cord Dohrmann CEO CFO COO CSO PAGE 2 1) On the call for the 9M 2021 interim report
Slide 4: Agenda
Agenda Highlights Financial performance 9M 2021 Scientific and operational performance 9M 2021 Outlook and Guidance 2021 PAGE 3
Slide 5: Strong performance and progress on all lanes
Strong performance and progress on all “lanes” 9M 2021 – Highlights & Lowlights Highlights Growth acceleration based on strong performance in all business lines Multiple new & extended integrated drug discovery & development alliances (EVOiR&D) Opening of J.POD® Redmond (US); initiation of J
Slide 6: Strong operational performance drives growth
Strong operational performance drives growth Financials 9M 2021 & FY 2021 guidance Progressing in all business lines Unchanged Outlook Group revenues up 20% Very good top-line growth expected (€ 431.0 m vs. 9M 2020: € 360.4 m) Total Group revenues € 550-570 m (2020: € 500.9 m) Like-for-like
Slide 7: Completion of public offering at NASDAQ (Ticker: EVO)
Completion of public offering at NASDAQ (Ticker: EVO) U.S. public offering to support resilient growth Expanding global investment position, scale and presence in the US Improving chances for market share gains, getting closer to partners with total raise of US$ 500 m1) Making set-up even more resil
Slide 8: Agenda
Agenda Highlights Financial performance 9M 2021 Scientific and operational performance 9M 2021 Outlook and Guidance 2021 PAGE 7
Slide 9: Main KPIs underline positive development
Main KPIs underline positive development Condensed income statement 9M 2021 – Evotec SE and subsidiaries in € m1) Revenue growth of 20% (excluding 9M 2021 9M 2020 Change portfolio and fx effects: 26%) driven by Revenues from contracts with customers 431.0 360.4 20% all business areas Planned inc
Slide 10: Strong revenue growth and anticipated gross margin effects
Strong revenue growth and anticipated gross margin effects Revenues & Gross margin overview Revenues from contracts Gross margin Base revenues: Excluding the effect of with customers (in € m) (in %) € 8.6 m Sanofi payments in Q1 2020 Base revenues Total Margin and negative fx effects of € 11.2 m,
Slide 11: Very strong organic top-line growth in Q3 2021
Very strong organic top-line growth in Q3 2021 Condensed income statement Q3 2021 – Evotec SE and subsidiaries in € m1) Q3 2021 Q3 2020 Change Q3 revenue growth of 23%; Revenues from contracts with customers 159.7 129.4 23% Just – Evotec Biologics contributes € 11.7 m, up 41% vs. Q3 2020 Gross mar
Slide 12: Revenues up in all business areas
Revenues up in all business areas Segment information 9M 2021 – Evotec SE and subsidiaries in € m1) Inter- EVT EVT segment Evotec Total revenues show good progress in Execute Innovate elimination Group all business areas EVT Execute total revenue growth up Revenues 429.8 101.9 (100.8) 431.0 17%;
Slide 13: Strong growth continues in third quarter
Strong growth continues in third quarter Revenue bridge 9M 2020 – 9M 2021 – Evotec SE and subsidiaries in € m 431.0 (11.2) 20% growth of Group revenues 90.4 360.4 351.8 fx effect: € (11.2) m (-3.1%) (8.6) Organic growth of € 90.4 m translates in organic growth rate of 26% Revenues Portfolio1)
Slide 14: Strong balance sheet as base for future growth
Strong balance sheet as base for future growth Balance sheet and liquidity – 30 September 2021 vs. 31 Dec. 2020 – Evotec SE & subsidiaries Balance sheet total Equity ratio Total assets, liabilities and equity in € m in % increased by 20.8% Equity ratio step up by 6.8 percentage points 1,462.9 1,
Slide 15: Agenda
Agenda Highlights Financial performance 9M 2021 Scientific and operational performance 9M 2021 Outlook and Guidance 2021 PAGE 14
Slide 16: Integrated business for drug discovery and development delivers
Integrated business for drug discovery and development delivers Comprehensive suite of next generation capabilities Five pillars powering our innovation hub Revenues generated through three core collaboration routes EVOiR&D Drug discovery & development for our partners Work packages typically provid
Slide 17: Continued strong demand for efficiency enhancing collaborations
Continued strong demand for efficiency enhancing collaborations EVOiR&D – Major achievements 9M 2021 Integrated drug discovery collaborations with e.g. Bicycle Therapeutics, Evommune, … Several new INDiGO agreements e.g., with Oxford Cannabinoid Technologies and third INDiGO programme with Ildon
Slide 18: Proving paradigm shift in iPSC partnership with BMS
Proving paradigm shift in iPSC partnership with BMS Using EVOpanOmics & EVOpanHunter – Development since 2016 & iPSC alliance in 2017 Oct 2018 Sep 2019 Sep 2020 Sep 2021 Nov 2021 neurodegeneration US$ 5 m – US$ 6 m – US$ 30 m – US$ 6 m – US$ 20 m – US$ 40 m – Development of novel Screening milesto
Slide 19: Protein degradation partnership is accelerating
Protein degradation partnership is accelerating Using EVOpanOmics & EVOpanHunter – Development since 2018 & Proteomics approach May 2020 Oct 2020 Mar 2021 June 2021 to targeted protein Screening Project Double-digit New collaboration in degradation milestone initiation m extension undisclosed therap
Slide 20: Bayer's eliapixant significantly decreased cough frequency
Bayer’s eliapixant significantly decreased cough frequency EVOroyalty example: P2X3 antagonist – eliapixant (BAY1817080) Positive outcome of Phase IIb trial Cough frequency in Phase IIb1) Multiple indications (PAGANINI) potential Change from baseline of 24-hour cough count by visit Statistically s
Slide 21: Evotec Inside – Fully leveraged pipeline gaining visibility
“Evotec Inside” – Fully leveraged pipeline gaining visibility Steady stream of high value catalysts in the near-to-medium term Molecule Therapeutic Area/Indication Partner Discovery Pre-clinical Phase I Phase II Phase III Selected pipeline events within next 18 – 24 months EVT201 Insomnia (GABA-A) e
Slide 22: J.POD - commercial biologics manufacturing
J.POD® - commercial biologics manufacturing EVOaccess – Progress and status J.POD® Redmond (US) – Facility completed in just 19 months Grand opening in August Production from a few kilograms to metric tons in the same facility Partner at every stage of the biologics value chain Aerial view of
Slide 23: EVOequity accelerates co-owning strategy
EVOequity accelerates co-owning strategy Operational VC model – diversified portfolio with multiple shots on goal At Equity Holding (≥20%) or Significant influence Academia Partners & BRIDGEs Minority Shareholdings (<20%) Starting Attractive portfolio points to fuel with External EVOequity Spin- sig
Slide 24: Keeping the promise
Keeping the promise ESG & Sustainability – Measures taken in 9M 2021 Responsible use of resources Sourcing of 100% renewable energy since January 2021 at all German sites Decision on replacement of heating system in building B95 in Abingdon (estimated savings of CO2e of ~800t per year as of Q2 2
Slide 25: Agenda
Agenda Highlights Financial performance 9M 2021 Scientific and operational performance 9M 2021 Outlook and Guidance 2021 PAGE 24
Slide 26: Strong year paves way for future growth
Strong year paves way for future growth Guidance 2021 confirmed Very good top-line growth expected Assumption based on current orders, prospective milestone payments Total Group revenues € 550-570 m (€ 565-585 m at constant exchange rates1)) EBITDA guidance confirmed – despite massive investment
Slide 27: Upcoming important dates
Upcoming important dates Financial calendar Quarterly Statement Q1 2021 11 May 2021 Virtual Annual General Meeting 2021 15 June 2021 Half-year 2021 Interim Report 11 August 2021 Quarterly Statement 9M 2021 11 November 2021 Virtual Capital Markets Day 02 March 2022 PAGE 26
Slide 28: Capital Markets Day on 02 March 2022
2e, evotec HRESEARCHNEVERSTOPS RIGHT NOW, WE HAVE TO WAIT. We remain virtual once again CAPITAL MARKETS DAY ON 02 MARCH 2022
Slide 29: Questions and Answers
Slide 30: Your contact: Volker Braun
Your contact: Volker Braun SVP Head of Global Investor Relations & ESG +49.(0).40.560 81-775 +49.(0).151.1940 5058 volker.braun@evotec.com
Slide 31: Appendix
Appendix PAGE 30
Slide 32: Completion of public offering at NASDAQ: Offering Summary
Completion of public offering at NASDAQ (Ticker: EVO) Offering Summary Issuer Evotec SE American Depositary Shares (“ADSs”) trade under the symbol “EVO” on NASDAQ Global Select Market; Ticker (Exchange) Existing ticker for public offering of Ordinary Shares (“Ordinary Shares”) on Frankfurt Stock Exc
Slide 33: Investments remain at a high level
Investments remain at a high level Liquidity bridge YTD Q3 2021 in € m -61.9 (58.5) 481.9 (41.7) 417.6 (22.8) 6.4 (14.7) 5.1 31 Dec 2020 Operating Capex J.POD1) Capex all other Equity Bank Loans Repayment of fx difference 30 Sep 2021 cash flow1) investments (incl. lease obligation & others Conv. Loa
Slide 34: Revenue base affects receivables
Revenue base affects receivables Days Sales Outstanding stabilized within target range of 50-60 days DSO quarterly and LTM DSO average in days Trade accounts receivables including receivables from associated companies DSO in days and other long-term investments 100 quarterly "BMS effect" increased
Slide 35: Our purpose is to go VERY long as ONE
Our purpose is to go VERY long as ONE – #researchneverstops Sustainable thinking is holistic and ensures long-term success Best possible environment for The “shared economy” in R&D employees and potential recruits Integrated platform for >800 partners Engagement & Commitment Sharing values of